<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529226</url>
  </required_header>
  <id_info>
    <org_study_id>CLOZ-AID</org_study_id>
    <secondary_id>2020-000091-37</secondary_id>
    <nct_id>NCT04529226</nct_id>
  </id_info>
  <brief_title>Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability &amp; Treatment-resistant Psychosis</brief_title>
  <acronym>CLOZ-AID</acronym>
  <official_title>A Randomized, Multicenter Clinical Trial to Assess the Efficacy and Safety of Clozapine vs Treatment as Usual for Treatment-resistant Psychosis in Adolescents and Young Adults With Intellectual Disability.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will prove whether a large number of people with intellectual disability&#xD;
      and treatment-resistant psychosis could benefit from the use of clozapine. Benefit will mean&#xD;
      a measurable significant improvement in subjects' clinical response and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement based on Clinical Global Impression-Schizophrenia (CGI-SCH) scale score.</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Overall Severity of Illness as measured by change from baseline to last study visit score&#xD;
Minimum value = 1 Normal, not ill Maximum value = 7 Among the most severely ill</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement based on Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Clinical improvement as measured by change from baseline to last study visit score&#xD;
Subjects rated from 1 to 7 on 30 different symptoms (items). Positive scale 7 Items. minimum score = 7, maximum score = 49 Negative scale 7 Items. minimum score = 7, maximum score = 49 General Psychopathology scale 16 Items. minimum score = 16, maximum score = 112&#xD;
PANSS Total score minimum = 30, maximum = 210</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement based on Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Clinical improvement as measured by change from baseline to last study visit score.&#xD;
SANS is split into 5 domains, and within each domain separate symptoms are rated through a 6-point scale from 0 (absent) to 5 (severe).&#xD;
SANS Total score minimum = 0, maximum = 125</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement based on the 5-level Quality of Life 5-dimensional questionnaire (Euro-QoL 5D-5L scale)</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Generic health status improvement measured by change from baseline to last study visit scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 28 days after the last investigational medicinal product administration</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Psychosis</condition>
  <condition>Intellectual Disability</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaceutical Form: Tablet ATC Code: N05AH02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week</description>
    <arm_group_label>Clozapine</arm_group_label>
    <other_name>Nemea</other_name>
    <other_name>Leponex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol, pimozide, olanzapine, risperidone, amisulpride</intervention_name>
    <description>Treatment as usual using first-generation or second-generation antipsychotics</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged between 16 and 40 years&#xD;
&#xD;
          -  Diagnosis of intellectual disability according to the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders DSM-5 (confirmed by a IQ Score between 35 and 70 in the&#xD;
             Kaufman test)&#xD;
&#xD;
          -  Diagnosis of psychosis according to the DSM-5 (confirmed by clinical interview).&#xD;
&#xD;
          -  Treatment Resistant to antipsychotic drugs except clozapine.&#xD;
&#xD;
          -  Behavioural disturbances and self-injurious behaviour over the last 6 months.&#xD;
&#xD;
          -  Written informed consent of patients or legal representative.&#xD;
&#xD;
          -  Negative pregnancy test (if apply)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leukocytes &lt; 3500/mm3 and neutrophils &lt; 2000/mm3.&#xD;
&#xD;
          -  Hypersensitivity to clozapine or excipients.&#xD;
&#xD;
          -  Myeloproliferative disorders&#xD;
&#xD;
          -  Uncontrolled epilepsy in the last 2 years.&#xD;
&#xD;
          -  Paralytic ileus in the last 3 months.&#xD;
&#xD;
          -  Diagnosis of an autism spectrum disorder&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Any diseases with clozapine contraindicated.&#xD;
&#xD;
          -  Any uncontrolled serious condition&#xD;
&#xD;
          -  Need of treatment with more than one antipsychotic drug or electroconvulsive therapy&#xD;
&#xD;
          -  Treatment with quinolones, drugs that cause agranulocytosis or drugs that affect the&#xD;
             cytochrome P-450 enzymes.&#xD;
&#xD;
          -  Risk of suicide based on the Columbia-Suicide Severity Rating Scale&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedicto Crespo Facorro, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andalusian Health Service</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Rosso Fernández, PhD</last_name>
    <phone>+34 955 013414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unidad de Salud Mental Comunitaria Andújar</name>
      <address>
        <city>Andújar</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Gómez Moreno</last_name>
      <email>cristinagomezmoreno@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro psicopedagógico Reina Sofía</name>
      <address>
        <city>Armilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge C Cervilla Ballesteros</last_name>
      <email>jcervilla@ugr.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental Comunitaria Cabra</name>
      <address>
        <city>Cabra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Carrion Exposito</last_name>
      <email>laura-ce85@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Rodríguez Penalva</name>
      <address>
        <city>Castril</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Cervilla Ballesteros</last_name>
      <email>jcervilla@ugr.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Sarramea Crespo</last_name>
      <email>fscferro69@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental Comunitaria Córdoba Sur</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Sarramea Crespo</last_name>
      <email>fscferro69@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Purísima Concepción Hermanas Hospitalarias</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Ballesteros</last_name>
      <email>jcervilla@ugr.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Cervilla Ballesteros</last_name>
      <email>jcervilla@ugr.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Villagran Romero</last_name>
      <email>jmaria.villagran.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia de Adultos María Dacia González Gordón</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Villagrán Romero</last_name>
      <email>jmaria.villagran.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia para personas con Discapacidad intelectual Gravemente Afectadas Vista Hermosa</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Villagran Romero</last_name>
      <email>jmaria.villagran.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental Comunitaria Montilla</name>
      <address>
        <city>Montilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Sarramea Crespo</last_name>
      <email>fscferro69@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental Comunitaria Montoro</name>
      <address>
        <city>Montoro</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando C Sarramea Crespo</last_name>
      <email>fscferro69@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Asistencial San Juan de Dios</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melquiades Leon Macias</last_name>
      <email>fermin.mayoral.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fermín Mayoral Cleries</last_name>
      <email>fermin.mayoral.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villablanca Serveis Assistencials</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Martínez Leal</last_name>
      <email>rmarleal@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia de gravemente afectados Virgen de la Caridad</name>
      <address>
        <city>Sanlúcar De Barrameda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Villagrán Romero</last_name>
      <email>jmaria.villagran.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Romero Guillena</last_name>
      <email>samuel.forqueta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicto Crespo-Facorro, Professor</last_name>
      <phone>+34671596675</phone>
      <email>benedicto.crespo.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Idalino Rocha, MSc</last_name>
      <phone>+34689366067</phone>
      <email>idalino.rocha@juntadeandalucia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Benedicto Crespo-Facorro, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Ruiz-Veguilla, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Ocupacional El Curtido</name>
      <address>
        <city>Ubrique</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rocío Torrecilla Olavarrieta</last_name>
      <email>rociotorrecillaol@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Pimozide</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

